Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Hoffmann-La Roche
University of Florida
Genentech, Inc.
UNC Lineberger Comprehensive Cancer Center
ImmunityBio, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Pittsburgh
National Cancer Institute (NCI)
University of Oklahoma
Maastricht University Medical Center
Alliance Foundation Trials, LLC.
Exelixis
Gustave Roussy, Cancer Campus, Grand Paris
Medical College of Wisconsin
Mario Negri Institute for Pharmacological Research
AGO Research GmbH
National Cancer Institute (NCI)
ARCAGY/ GINECO GROUP
Immatics US, Inc.
Centre Hospitalier Universitaire de Besancon
Nykode Therapeutics ASA
Grupo Español de Investigación en Cáncer de Ovario
Universitaire Ziekenhuizen KU Leuven
OHSU Knight Cancer Institute
Fate Therapeutics
Hoffmann-La Roche
Peter MacCallum Cancer Centre, Australia
Fate Therapeutics
Gradalis, Inc.
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
Hoffmann-La Roche
Duke University
MultiVir, Inc.